IP 66: may show strong antagonism toward postsynaptic alpha-receptors & slight agonism towards presynaptic beta-receptors [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 162845 |
| SCHEMBL ID | 3628739 |
| MeSH ID | M0121599 |
| Synonym |
|---|
| ip 66 |
| 1-[2-ethoxy-2-(pyridin-3-yl)ethyl]-4-(2-methoxyphenyl)piperazine |
| 58013-09-5 |
| SCHEMBL3628739 |
| 1-(2-ethoxy-2-(3'-pyridyl)ethyl)-4-(2'-methoxyphenyl)piperazine |
| ip-66 |
| piperazine, 1-(2-ethoxy-2-(3-pyridinyl)ethyl)-4-(2-methoxyphenyl)- |
| ip66 |
| DTXSID60973600 |
| (+/-)-ip 66;(+/-)-ip66 |
| (+/-)-ip-66 |
| ()-ip-66 |
| ()-ip 66;()-ip66 |
| PD161025 |
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 4 (100.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.
| This Compound (79.24) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 5 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||